DANIEL BODEK

Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology UNION, NJ NPI 1306266408

General Payments — all program years on this page

$411.35

  • Category: General Payments
  • Program years: PY2022–2024
  • Record count: 23
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $362.70 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $362.7020

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2022 $14.011
2023 $34.642
2024 $362.7020

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1103341162 ABBVIE INC. $14.64 07/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103341164 ABBVIE INC. $17.41 09/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133639586 Gilead Sciences, Inc. $15.89 06/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133639588 Gilead Sciences, Inc. $16.15 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137491564 Takeda Pharmaceuticals U.S.A., Inc. $21.51 05/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137491568 Takeda Pharmaceuticals U.S.A., Inc. $19.69 05/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137491572 Takeda Pharmaceuticals U.S.A., Inc. $14.86 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144161991 Madrigal Pharmaceuticals $17.81 10/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144161993 Madrigal Pharmaceuticals $13.78 12/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147730322 QOL Medical, LLC $17.83 02/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147730324 QOL Medical, LLC $25.15 03/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147730326 QOL Medical, LLC $22.23 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147730328 QOL Medical, LLC $21.14 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147730330 QOL Medical, LLC $22.23 08/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147730332 QOL Medical, LLC $23.98 09/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147730334 QOL Medical, LLC $20.60 11/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153553555 Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.96 09/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153574844 Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.18 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153683391 Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.30 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153712936 Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.36 11/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.